Verastem Inc (NASDAQ:VSTM) fell 5.4% on Thursday after Zacks Investment Research downgraded the stock from a hold rating to a sell rating. The company traded as low as $3.15 and last traded at $3.17. 3,763,545 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 2,478,497 shares. The stock had previously closed at $3.35.
A number of other brokerages have also recently weighed in on VSTM. BidaskClub cut Verastem from a “hold” rating to a “sell” rating in a research note on Tuesday, December 11th. ValuEngine cut Verastem from a “buy” rating to a “hold” rating in a research note on Monday, December 17th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (down previously from $13.00) on shares of Verastem in a research note on Thursday. Finally, Raymond James reduced their price objective on Verastem from $12.00 to $6.00 and set an “outperform” rating for the company in a research note on Thursday. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $12.97.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Principal Financial Group Inc. purchased a new stake in shares of Verastem during the fourth quarter worth approximately $35,000. Amalgamated Bank purchased a new stake in shares of Verastem during the fourth quarter worth approximately $35,000. MML Investors Services LLC raised its stake in shares of Verastem by 70.0% during the fourth quarter. MML Investors Services LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 7,000 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Verastem during the fourth quarter worth approximately $62,000. Finally, Blueshift Asset Management LLC purchased a new stake in shares of Verastem during the fourth quarter worth approximately $62,000. Institutional investors own 59.21% of the company’s stock.
Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.23. The company had revenue of $1.21 million for the quarter, compared to analysts’ expectations of $5.56 million. Analysts forecast that Verastem Inc will post -1.95 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2019/03/15/verastem-vstm-stock-price-down-5-4-on-analyst-downgrade.html.
About Verastem (NASDAQ:VSTM)
Verastem, Inc, operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies.
Featured Article: Can individual investors take part in an IPO?
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.